Advocacy partner: National Fragile X Foundation
About the National Fragile X Foundation
Since 1984, the National Fragile X Foundation has supported and empowered families impacted by Fragile X, by providing the knowledge, resources, and tools they need to navigate daily challenges and support individuals in reaching their full potential. Our work focuses on four strategic areas: promoting advocacy, providing education, advancing research, and improving treatments.
Contact: Kristin Bogart – Senior Director, Development and Communications
Phone: (800) 688-8765
Email: [email protected]
Resources
In this 90-second video, the National Fragile X Foundation answers the frequently asked question, “What is Fragile X?” by explaining Fragile X Syndrome, the premutation, and its associated conditions, as well as how Fragile X is inherited.
What is the Fragile X Premutation?
Learn what the Fragile X premutation is in just 90 seconds. This short animated video from the National Fragile X Foundation explains how the Fragile X premutation affects individuals and families—and why awareness matters.
Treatment and Intervention Recommendations for Fragile X
The NFXF’s family-friendly Treatment Recommendations are in-depth documents developed by NFXF staff, members of the NFXF’s Fragile X Clinical & Research Consortium (FXCRC), and other Fragile X professionals, and reviewed and edited by the entire FXCRC.
Transitioning to Adulthood Checklist
Transitioning into adulthood can be an overwhelming task. We’re here to help! Here is a helpful checklist of things to consider as your loved one with Fragile X syndrome ages.
Upcoming Events
[tribe_events_list category=”national-fragile-x-foundation” street=”yes” city=”yes” region=”yes” country=”yes” thumbnail=”yes”]
About Advocacy Partners
The information above is provided by our partner. Learn more about our advocacy partners here.
Recent Posts
- FRAXA backs upcoming Phase 2b trial of SPG601 for fragile X syndrome
- Daily use of diabetes drug metformin eases hyperactivity in fragile X boys
- USC researchers net $6.3M federal grant to study fragile X mutations
- 1st patient enrolled in Phase 2 trial of treatment for fragile X syndrome
- Phase 2 trial of experimental oral treatment enrolling fragile X males
- SPG601 calms brain activity in men with fragile X, helping them to focus
- Cannabidiol gel ZYN002 for fragile X fails to meet goal in clinical trial
- Fragile X, ASD children have distinct brain network patterns
- SPG601 granted orphan drug status in EU for treating fragile X
- Supporters getting ready for Fragile X Awareness Month
